A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer (Prospect)
This study is currently recruiting participants.
Verified February 2013 by BN ImmunoTherapeutics
Sponsor:
BN ImmunoTherapeutics
Information provided by (Responsible Party):
BN ImmunoTherapeutics
ClinicalTrials.gov Identifier:
NCT01322490
First received: March 23, 2011
Last updated: June 7, 2013
Last verified: February 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is currently recruiting participants. |
|---|---|
| Estimated Study Completion Date: | August 2016 |
| Estimated Primary Completion Date: | December 2015 (Final data collection date for primary outcome measure) |